Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials


In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.


Currently viewing trials
(Last updated: October 24, 2020)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2 (inherited)

Chemotherapy

Hormone Therapy

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Screening

Support/Education

Surveys/Interviews/Registries

Close

AKT

ALK

AR

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

RB

ROS1

TP53

1

NEAREST SITE: 2 miles
Zuckerberg San Francisco General Hospital
San Francisco,CA

VISITS: 3 or 5 visits, over 5 years

PHASE: III

NCT ID: NCT03233191

Breast Cancer Screening Based on Individual Risk Factors and Comparing the Effectiveness of 3D to 2D Mammography

Tomosynthesis Mammographic Imaging Screening Trial (TMIST) Scientific Title

Purpose
To study if risk-based screening for breast cancer is as safe and effective as age-based screening and if (3D) mammography is better than (2D) mammography at finding early-stage tumors.
Who is this for?
Women, age 45 to 74, who have never been diagnosed with DCIS or breast cancer. You must not have had a screening mammogram within the last 11 months    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Digital mammogram (2D)</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">if you are premenopausal or postmenopausal with 1 risk factor, mammogram, once a year, for five years</li> <li class="seamTextUnorderedListItem">if you are postmenopausal, mammogram, every 2 years, for five years</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Digital tomosynthesis mammogram (3D)</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">if you are premenopausal or postmenopausal with 1 risk factor, mammogram, once a year, for five years</li> <li class="seamTextUnorderedListItem">if you are postmenopausal, mammogram, every 2 years, for five years</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Most breast cancer screening guidelines are based upon a woman's age--not her individualized risk of developing breast cancer. </li> <li class="seamTextUnorderedListItem">For this trial, you will receive annual mammograms if you are premenopausal or postmenopausal with at least one risk factor.</li> <li class="seamTextUnorderedListItem">Risk factors if you are 45-69: dense breasts, a first degree relative with breast cancer, an inherited genetic mutation that increases your risk of developing cancer, or taking hormone therapy.</li> <li class="seamTextUnorderedListItem">Risk factors if you are 70-74: dense breasts or taking hormone therapy.</li> <li class="seamTextUnorderedListItem">Digital tomosynthesis (3D) mammography is approved by the FDA but is not considered the standard of care for breast cancer screening.</li> <li class="seamTextUnorderedListItem">Digital (2D) mammography is the standard of care for breast cancer screening.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03233191' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ecog-acrin.org/tmist' target='_blank'>ECOG-ACRIN Cancer Research Group Trial Information Page: TMIST</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/symptoms/testing/types/dig_tomosynth' target='_blank'>Breastcancer.org: Digital Tomosynthesis</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/breast_center/treatments_services/breast_cancer_screening/digital_mammography/index.html' target='_blank'>Johns Hopkins Medicine: Digital Mammography</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2017/tmist-breast-cancer-screening' target='_blank'>NCI Cancer Currents Blog: TMIST Trial Aims to Provide Clarity on Breast Cancer Screening Approaches</a> </li></ul>
See more
2

NEAREST SITE: 3 miles
University of California San Francisco (UCSF)
San Francisco,CA

VISITS: Weekly visits for 4 months

PHASE: I

NCT ID: NCT01042379

Personalized Treatment Before Surgery For Stage II-III Breast Cancer: The I-SPY 2 Trial

I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2) Scientific Title

Purpose
To compare the safety and anti-cancer activity of giving the standard of care to giving the standard of care plus an experimental drug that was chosen based on your tumor's biomarkers.
Who is this for?
People with stage II or stage III breast cancer who have not yet started treatment and whose cancer is considered high-risk for recurrence.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups, and receive the following before surgery: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care therapy</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care therapy</li> <li class="seamTextUnorderedListItem">At least one experimental therapy that is chosen based on your tumor's biomarkers</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">4 MRIs</li> <li class="seamTextUnorderedListItem">2 biopsies</li> <li class="seamTextUnorderedListItem">Blood draws</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This clinical trial has an <q>adaptive design.</q> This means that experimental drugs will be added during the trial, and experimental drugs that are not more effective than standard of care therapy will be removed. </li> <li class="seamTextUnorderedListItem">At least 80% of people who enroll will receive an experimental drug. </li> <li class="seamTextUnorderedListItem">This trial will use several types of experimental drugs: immunotherapies, anti-hormone therapies, PARP inhibitors, CDK 4/6 inhibitors, and others. </li> <li class="seamTextUnorderedListItem">All drugs will be given prior to surgery (neoadjuvant therapy), this allows researchers to see how your tumor is responding to the drugs. </li> <li class="seamTextUnorderedListItem">The information that researchers gain from studying your tumor's response will be used to help decide which drugs should be given to people who join the trial after you.</li> <li class="seamTextUnorderedListItem">For this trial, cancer is considered high-risk for recurrence if it tests MammaPrint High or MammaPrint Low (but only if your tumor is ER- or HER2+).</li> <li class="seamTextUnorderedListItem">MammaPrint is a genomic test (analyzes your tumor) that gives two types of recurrence scores, low risk or high risk.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01042379' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://ispy2.org/' target='_blank'>Quantum Leap Healthcare Collaborative Study Website: I-SPY 2</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/MammaPrint' target='_blank'>Wikipedia: MammaPrint</a> </li><li class='seamTextUnorderedListItem'><a href='https://pubmed.ncbi.nlm.nih.gov/32701140/' target='_blank'>Journal Article: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial</a> </li></ul>
See more
3

NEAREST SITE: 210 miles
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT03723928

Imaging and Tumor Mark Tests to Monitor Metastatic HR Positive, HER2 Negative Breast Cancer

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer (SWOG-S1703) Scientific Title

Purpose
To study if blood tests that look for tumor markers are as good as or better than imaging with PET and/or CT scans (the current standard of care) to determine if a tumor is growing.
Who is this for?
People with metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who are planning to have first line treatment for metastatic disease or have started treatment within the past month, and have at least one elevated tumor marker.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Standard of care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Imaging (CT and/or PET scans), at least every 3 months, ongoing</li> <li class="seamTextUnorderedListItem">Tumor Marker Test, if ordered by your doctor</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor Marker Tests, every 1 to 2 months, ongoing</li> <li class="seamTextUnorderedListItem">Imaging (CT and/or PET scans), only if need is shown by a Tumor Marker Test</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draws</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This <span class="highlight">imaging</span> <span class="highlight">trial</span> will compare using blood tests to PET/CT scans for monitoring tumor growth. </li> <li class="seamTextUnorderedListItem">The tumor markers that will be tested for in this study are CA 15-3, CA27.29, and CEA.</li> <li class="seamTextUnorderedListItem">The imaging tests will be those ordered by your doctor.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03723928' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/testing/types/blood_marker' target='_blank'>Breastcancer.org: Blood Marker Tests</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/about-us/collaborations/top-five-list-oncology/choosing-wisely®-top-five-cancer-related-tests-procedures-and-treatments-many-patients-do-not-need/topic-4-follow-tumor-marker-tests-and-imaging-tests-people-treated-breast-cancer' target='_blank'>ASCO Cancer.net: Follow-up Tumor Marker Tests and Imaging Tests for People Treated for Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet' target='_blank'>NCI: Tumor Markers</a> </li><li class='seamTextUnorderedListItem'><a href='https://ozarkscancerresearch.org/wp-content/uploads/2019/04/SWOG-S1703.pdf' target='_blank'>Cancer Research for the Ozarks: Trial Information Page</a> </li></ul>
See more
4

NEAREST SITE: 666 miles
University of Washington Medical Center
Seattle,WA

VISITS: 1 visit

PHASE: II

NCT ID: NCT02398773

Predicting Which Tumors in People With Newly Diagnosed Metastatic ER+ Breast Cancer Will Respond to Hormone Therapy

[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients With Newly Diagnosed Metastatic Breast Cancer (EAI142) Scientific Title

Purpose
To see if FES-PET/CT scans can predict how ER+ breast cancer will respond to anti-hormone therapy.
Who is this for?
People with newly diagnosed metastatic (stage IV) breast cancer who have not yet received hormone therapy for metastatic disease and who have at least one tumor that is estrogen receptor positive (ER+).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> All participants will undergo the following up to 30 days before starting standard hormone therapy: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FES tracer, by IV over 2 minutes</li> <li class="seamTextUnorderedListItem">followed by PET/CT imaging</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">May undergo a second FES-PET/CT at least 24 hours and no later than 10 days after the initial study</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tracers are chemicals that are used to find cancer cells in the body. </li> <li class="seamTextUnorderedListItem">This <span class="highlight">imaging</span> <span class="highlight">trial</span> will use the tracer fluoroestradiol (FES)--a tracer that finds estrogen receptors in breast cancer tumors. </li> <li class="seamTextUnorderedListItem">Giving an FES tracer before a PET/CT scan may help doctors find ER+ breast cancer cells that have spread to other parts of the body (metastasized).</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02398773' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/clinical-trials/cls-20347030' target='_blank'>Mayo Clinic Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologyinfo.org/en/info.cfm?pg=pet' target='_blank'>RadiologyInfo.org: Positron Emission Tomography - Computed Tomography (PET/CT)</a> </li><li class='seamTextUnorderedListItem'><a href='http://clincancerres.aacrjournals.org/content/23/2/407' target='_blank'>AACR: Estrogen Receptor Binding and Glycolytic Activity Predict Progression-Free Survival on Endocrine Therapy</a> </li></ul>
See more
5

NEAREST SITE: 1387 miles
University of Oklahoma Health Sciences Center
Oklahoma City,OK

VISITS: 2 visits over 4 months

PHASE: II

NCT ID: NCT04316117

Using PET/CT Scans to See How Breast Cancer That Has Spread to the Bones is Responding to Therapy

FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE Scientific Title

Purpose
To study if PET/CT scans with a FDG tracer find tumors missed by standard of care imaging and can see how breast cancer tumors that have spread to the bones are responding to therapy.
Who is this for?
People with stage IV (metastatic) breast cancer that has spread to their bones and who have not received more than 3 chemotherapies for metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FDG tracer, by IV, followed by PET/CT scan, 2 times (1 scan before treatment, 1 scan 3 months after starting treatment)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">This <span class="highlight">imaging</span> <span class="highlight">trial</span> will use a tracer called FDG (fluorodeoxyglucose). </li> <li class="seamTextUnorderedListItem">FDG produces color-coded images that show normal and cancerous tissue.s tissue.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04316117' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ecog-acrin.org/clinical-trials/ea1183-educational-materials' target='_blank'>ECOG-ACRIN Study Information Page: FEATURE</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/tests/pet-ct-scan' target='_blank'>Cancer Research UK: PET-CT Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.docpanel.com/blog/post/understanding-your-fdg-pet-scan' target='_blank'>Docpanel: Understanding Your FDG PET Scan</a> </li></ul>
See more
6

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1 to 2 visits

PHASE: I

NCT ID: NCT03604315

An Experimental PET/CT Scan to Find PARP-Expressing Tumor Cells

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CT Scientific Title

Purpose
To study the safety and effectiveness of using a PET/CT scan with the experimental tracer F-18.
Who is this for?
People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer or DCIS.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">F-18 tracer, by IV, then a PET/CT scan</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">The tracer used in this <span class="highlight">imaging</span> <span class="highlight">trial</span> is called fluorine F 18 fluorthanatrace (F-18)--it binds to PARP expressing tumor cells (PARP is a protein over expressed in certain cancers). </li> <li class="seamTextUnorderedListItem">You do not need to have an inherited BRCA1/2 mutation to enroll in this trial but researchers are studying whether F-18 works better in inherited BRCA1/2+ cancers. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of solid tumors.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03604315' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diagnostics/10123-pet-scan' target='_blank'>Cleveland Clinic: PET Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fluorine-f-18-fluorthanatrace' target='_blank'>NCI Drug Dictionary: Fluorine F 18 Fluorthanatrace</a> </li></ul>
See more
7

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1 visit every 2 weeks, and 5 to 10 days of radiation therapy

PHASE: I

NCT ID: NCT03524170

Immunotherapy and Radiation Therapy for Metastatic Hormone Positive, HER2 Negative Breast Cancer

RACHEL1: A Phase I Radiation and CHEckpoint bLockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Scientific Title

Purpose
To study the best dose, safety, and effects (good and bad) of using the immunotherapy M7824 in combination with radiation therapy.
Who is this for?
People with metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer. You must have at least two sites of metastatic disease as seen by imaging.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">M7824, by IV, every 2 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Radiation therapy, daily, 5-10 days</li> <li class="seamTextUnorderedListItem">Biopsy after 2 months</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">M7824 (MSB0011359C) is a protein with two components: PD-L1 antibody and TGF-β receptor. </li> <li class="seamTextUnorderedListItem">M7824 is currently being used for research purposes only.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03524170' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://stm.sciencemag.org/content/10/424/eaan5488' target='_blank'>Science Translational Medicine: M7824</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/publications/oncolog/radiation-may-enhance-immunotherapy-for-solid-tumors.h10-1591413.html' target='_blank'>MD Anderson Cancer Center: Radiation May Enhance Immunotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976948/' target='_blank'>Journal Article: Evolution of Radiation Therapy in MBC</a> </li></ul>
See more
8

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT02152254

Molecular Profiling-Based Targeted Therapies for Metastatic Breast Cancer (Basket Study)

A Basket Study: Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer: Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT 2) Scientific Title

Purpose
To study if choosing cancer treatment based on your tumor's molecular profile is more effective than the current standard of care.
Who is this for?
People with metastatic (stage IV) breast cancer who have been treated with standard of care therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> All participants will have their tumor biopsy undergo molecular profiling. Participants who have tumors with no molecular abnormality will receive an FDA-approved therapy. Participants with a molecular abnormality will then be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Targeted therapy based on molecular profiling</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physican's choice standard of care</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Patients whose tumors progress will have the option of crossing over to the other treatment arm</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Molecular profiling of a tumor may identify genetic mutations or biomarkers that suggest the tumor is likely to respond to a currently available targeted therapy. </li> <li class="seamTextUnorderedListItem">It is not known if choosing metastatic breast cancer treatment based on the tumor's molecular profile is more effective than the current standard of care. </li> <li class="seamTextUnorderedListItem">All patients who enroll in this study will have molecular profiling performed on a biopsy of their tumor. </li> <li class="seamTextUnorderedListItem">If there is no mutation or biomarker found, the patient will receive the treatment their doctor determines is the best option. </li> <li class="seamTextUnorderedListItem">If a mutation or biomarker is found and there is an FDA-approved drug for the tumor type, patients will be offered that treatment. </li> <li class="seamTextUnorderedListItem">If there is a mutation or biomarker found but no FDA-approved drug that targets it, patients will be randomly assigned to either a targeted therapy or the standard of care.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer. </li> <li class="seamTextUnorderedListItem">Targets or mutations: vary based on test results.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02152254' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825646/' target='_blank'>Journal Article: Molecular Profiling for Breast Cancer</a> </li></ul>
See more
9

NEAREST SITE: 1678 miles
University of Wisconsin Carbone Cancer Center
Madison,WI

VISITS: 1 visit every 3 to 4 weeks, ongoing

PHASE: NA

NCT ID: NCT04174352

Imaging to Personalize Amount of Tamoxifen in Advanced, ER+, HER2- Breast Cancer With a ESR1 Mutation

A Pilot Study of FES Imaging to Optimize Tamoxifen Dose for Metastatic Breast Cancer Patients With ESR1 Mutations Scientific Title

Purpose
To study if FES-PET/CT scans can help find a personalized dose of tamoxifen (Nolvadex®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV), estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer that tests positive for a ESR1 mutation.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">FES PET/CT scan, every 3 to 4 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®) is an anti-estrogen therapy used to treat hormone-sensitive breast cancer.</li> <li class="seamTextUnorderedListItem">ESR1 mutations in breast cancer may affect how well tamoxifen works against tumor cells. </li> <li class="seamTextUnorderedListItem">Tracers are chemicals that are used to find cancer cells in the body during a PET scan. The <span class="highlight">imaging</span> <span class="highlight">trial</span> will use the tracer fluoroestradiol (FES)--it finds estrogen receptors in breast tumors. </li> <li class="seamTextUnorderedListItem">The FES tracer may also show how tamoxifen is affecting your tumors. Researchers may use this information to increase your dose of tamoxifen.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ESR1</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04174352' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/hormonal-therapy-metastatic-breast-cancer' target='_blank'>ASCO Cancer.net: Hormonal Therapy for Metastatic Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal/serms/tamoxifen' target='_blank'>Breastcancer.org: Tamoxifen</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.targetedonc.com/view/more-effective-therapies-needed-for-patients-with-esr1mutated-breast-cancer' target='_blank'>Targeted Oncology: More Effective Therapies Needed For Patients With ESR1-Mutated Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.karger.com/Article/FullText/481428' target='_blank'>Journal Article: Are We Ready to Use ESR1 Mutations in Clinical Practice</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.ijcem.com/files/ijcem0076055.pdf' target='_blank'>Journal Article: The Role of PET Imaging Probes for Early Monitoring the Response to Tamoxifen</a> </li></ul>
See more
10

NEAREST SITE: 1739 miles
Washington University School of Medicine
Saint Louis,MO

VISITS: At least 7 visits over 3 years

PHASE: II

NCT ID: NCT03862131

PROactive Evaluation to Reduce Treatment-Related Heart Problems (PROACT)

PROactive Evaluation of Function to Avoid CardioToxicity Scientific Title

Purpose
To look at whether MyoStrain® measurements are as good as or better than traditional MRI measurements for predicting and reducing a patient's risk of developing treatment-related heart problems.
Who is this for?
People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer scheduled to start cancer therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cardiac MRI at 1 month, 3 months, 6 months, 1 year, 2 years, and 3 years after the baseline visit</li> <li class="seamTextUnorderedListItem">MyoStrain® measurements</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cardiac MRI at 1 month, 3 months, 6 months, 1 year, 2 years, and 3 years after the baseline visit</li> <li class="seamTextUnorderedListItem">Standard of care MRI measurements (LVEF and LVEDV/LVESV)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MyoStrain® analyzes data collected from MRI heart scans to assess a patient's risk of developing heart problems.</li> <li class="seamTextUnorderedListItem">This <span class="highlight">imaging</span> <span class="highlight">trial</span> will compare if measurements taken by MyoStrain® are better able to predict who will develop heart problems from cancer therapies than the traditional measurements taken by MRI.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03862131' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.myocardialsolutions.com/' target='_blank'>Myocardial Solutions Product Information Page: MyoStrain®</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nccn.org/patients/resources/life_with_cancer/managing_symptoms/cardiac_toxicity.aspx' target='_blank'>National Comprehensive Cancer Network: Cardiac Toxicity</a> </li></ul>
See more
11

NEAREST SITE: 2567 miles
Memorial Sloan Kettering Cancer Center
New York,NY

VISITS: 1-2 visits

PHASE: NA

NCT ID: NCT01916122

A New Approach to Studying How ER+ Tumors Respond to Treatment

Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status Scientific Title

Purpose
To study whether PET/CT scans that use a FES tracer can show if ER+ breast cancer is responding to therapy.
Who is this for?
People with stage I, stage II, stage III, or metastatic (stage IV) estrogen receptor positive (ER+) breast cancer who are receiving treatment at Memorial Sloan Kettering Cancer Center.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FES tracer, by IV</li> <li class="seamTextUnorderedListItem">followed by PET/CT scan</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells. </li> <li class="seamTextUnorderedListItem">A tracer called 16a-18F-fluoroestradiol (FES) looks for and attaches to estrogen receptors. </li> <li class="seamTextUnorderedListItem">Researchers are using this <span class="highlight">imaging</span> <span class="highlight">trial</span> to study if the tracer FES can be used to monitor the effect a cancer therapy is having on the cancer cells.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01916122' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/ency/article/003827.htm' target='_blank'>MedlinePlus: PET Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.sciencedaily.com/releases/2018/08/180806104245.htm' target='_blank'>Science Daily: PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer</a> </li></ul>
See more
12

NEAREST SITE: 2693 miles
Brigham and Women's Hospital
Boston,MA

VISITS: 1 visit every 6 months, for 2 years

PHASE: NA

NCT ID: NCT04030507

Using MRIs to Screen for Brain Metastases in Advanced Breast Cancer

Screening Magnetic Resonance Imaging of the Brain in Patients With Metastatic Breast Cancer Managed With First/Second Line Chemotherapy or Inflammatory Breast Cancer Managed With Definitive Intent: A Prospective Study Scientific Title

Purpose
To study if using MRIs to screen for brain metastases (breast cancer that has spread to the brain) is safe and finds brain metastases earlier than the standard of care (no screening).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer who will be starting their first or second chemotherapy for advanced disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 3 groups depending upon your cancer subtype: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Triple negative</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Inflammatory</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Hormone positive or HER2 positive</i> </p> <p class="seamTextPara"> People in Group 3 will be randomly assigned to receiving screening or no screening </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Screening group</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">No screening group</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No brain MRIs</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain metastases (brain mets) is when breast cancer has spread to the brain. </li> <li class="seamTextUnorderedListItem">The standard of care for metastatic breast cancer does not include ongoing screening for brain metastases.</li> <li class="seamTextUnorderedListItem">This <span class="highlight">imaging</span> <span class="highlight">trial</span> will use regularly scheduled MRIs (magnetic resonance imaging) to look for brain mets.</li> <li class="seamTextUnorderedListItem">Researchers believe adding brain metastases screening to the standard of care will help doctors find brain mets earlier--when they are smaller and potentially easier to manage.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04030507' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/mri/about/pac-20384768' target='_blank'>Mayo Clinic: Brain MRI</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologybusiness.com/topics/policy/brain-mri-could-id-metastases-breast-cancer-patients-guidelines-dont-recommend-it' target='_blank'>Radiology Business: Brain MRI Could ID Metastases in Breast Cancer Patients</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancertodaymag.org/Pages/Spring2019/Looking-for-Brain-Metastases.aspx' target='_blank'>Cancer Today: Looking for Brain Metastases</a> </li></ul>
See more